Abstract: A tachykinin antagonist is useful, alone or in conjunction with other agents, for altering circadian rhythmicity and alleviating circadian rhythm disorders and for enhancing and improving the quality of sleep.
Abstract: A formulation for the treatment of a parasitic skin disease includes a parasiticide to kill the parasite. The formulation also includes a polymer effective to increase retention of the formulation on the skin, and to reduce absorption of the formulation into the skin. Alternatively, the formulation may include a polymer such as a beta-sheet breaker peptide which is effective to increase absorption of the insecticide into the head lice and/or the eggs of the head lice. The formulation also includes a vehicle for the polymer and the parasiticide.
Abstract: The present invention is concerned with new, previously unsuggested, therapeutic uses of dl-THP (dl-tetrahydropalmatine) including anxiety disorders, seizures, and status epilepticus.
Type:
Grant
Filed:
March 28, 2001
Date of Patent:
February 18, 2003
Assignee:
The Hong Kong University of Science & Technology
Abstract: The present invention provides a percutaneously applicable preparation containing an antidementia medicament, wherein the antidementia medicament is incorporated a higher alcohol, a lactate of a higher alcohol, an ester of a higher fatty acid and a lower alcohol, or an ester of a fatty acid having 6-18 carbon atoms and propyleneglycol. The present invention also provides a rectum applicable preparation containing an antidementia medicament, wherein the antidementia medicament is incorporated a tiriglyceride of a fatty acid and/or a water-soluble macromolecule.
Abstract: This invention relates to compounds which have activity as 5-HT1A agonists and antagonists which may be useful for the treatment of anxiety, depression, cognitive deficits, and prostate cancer, having the formula
wherein: X is a moiety selected from the group of:
n is selected from the integers 1 through 5; R1 is optionally substituted aryl or mono or bicyclic heteroaryl, with a proviso that heteroaryl is not thiadiazole; R2 is H or alkyl; R3 is H, COR5, COOR5, and CONR5R6; R4 is H, alkyl, alkenyl, alkynyl, aryl, mono or bicyclic heteroaryl, aralkyl, and mono or bicyclic heteroaralkyl, wherein the aryl or heteroaryl groups are optionally substituted; R5 and R6 are H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl, and noradamantyl or R5 and R6 taken together may form a 5-7 membered azacyclic ring, optionally containing an additional heteroatom selected from O, S, or NR4; when R5 or R6 are chosen from cycloalkyl or cycloalkenyl, the cyclic group may optionally
Type:
Grant
Filed:
March 27, 2002
Date of Patent:
February 11, 2003
Assignee:
Wyeth
Inventors:
Wayne E. Childers, Michael G. Kelly, Yvette L. Palmer, Edward J. Podlesny
Abstract: Compositions and methods for the prevention of adhesion development involve the administration of therapeutic formulations of a halogenated organic compound to a patient in need of treatment. The formulations can include suitable carriers for optimal administration.
Abstract: Agonists of A2A adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the treatment of the inflammatory response of mammalian tissue.
Type:
Grant
Filed:
August 9, 2000
Date of Patent:
February 4, 2003
Assignees:
University of Virginia Patent Foundation, University of Virginia
Inventors:
Joel M. Linden, Gail W. Sullivan, W. Michael Scheld
Abstract: This invention relates to a composition containing the three active ingredients: a) one or more phosphatidyl serines, b) one or more methyl transporters, and c) one or more compounds selected from methyl and methylene donors.
Type:
Grant
Filed:
April 25, 2001
Date of Patent:
February 4, 2003
Assignee:
Merck Patent Geseilschaft Mit Beschrankter Haftung
Abstract: A method for increasing chick production by increasing the level of L-DOPA in the bloodstream of breeder hens is described. Chick production is increased by increasing rates of egg laying, fertility of laid eggs, and number of fertile eggs that hatch. Methods for reducing the effects of stress on egg laying by increasing the level of L-DOPA in the bloodstream of breeder hens are also described.
Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone.
Type:
Grant
Filed:
June 11, 2001
Date of Patent:
January 14, 2003
Assignee:
Sepracor, Inc.
Inventors:
Thomas P. Jerussi, Chrisantha H. Senanayake, Paul D. Rubin, Yaping Hong, Roger A. Bakale, Tingjian Xiang, Fran A. McConville
Abstract: This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.
Type:
Grant
Filed:
November 5, 1999
Date of Patent:
December 31, 2002
Assignees:
GPI NIL Holdings, Inc., Johns Hopkins University School of Medicine
Inventors:
Joseph P. Steiner, Solomon Snyder, Gregory S. Hamilton, Ted Dawson
Abstract: This invention relates to formulations for the prevention of infection and/or abnormal conditions of mucosae and/or skin caused by any pathogen and/or any disease, and more particularly for the prevention of sexually transmitted infections specially HIV and HSV. This invention also relates to formulations for the treatment of infection and/or abnormal conditions of skin and/or mucosae and more particularly for the treatment of herpetic lesions. The formulations could be used as a prophylactic agent to prevent accidental infection of health care workers. The formulations could be used for the healing and/or treatment of burn wounds and prevention of further infection. This invention also relates to the development of a unique vaginal/ano-rectal applicator for the uniform delivery of any topical formulations to treat and/or prevent any infection and/or abnormal conditions of mucosa cavity caused by any pathogen and/or disease.
Abstract: The present invention relates to the new use of glucosamine and/or its derivatives for the preparation of a therapeutical composition for treating and quick relief of itching and/or local pain which results from a variety of causes. The invention further relates to therapeutical compositions for use in this treatment.
Abstract: This invention relates to a method of inhibiting tumor cell adhesion, pain, and inflammation at a wound during a surgical procedure by delivering an irrigation solution containing a tumor cell anti-adhesion agent and a plurality of additional agents to an operative site during the surgical procedure. In addition, methods of inhibiting tumor cell attachment and implantation during a surgical procedure as well as inhibiting tumor metastasis during a surgical procedure are also provided.
Type:
Grant
Filed:
September 11, 2000
Date of Patent:
December 10, 2002
Assignee:
Omeros Corporation
Inventors:
Gregory A. Demopulos, Pamela Pierce-Palmer, Jeffrey M. Herz, Darrell L. Tanelian
Abstract: A pharmaceutically acceptable topical formulation for the treatment and/or prevention of skin ailments, more particularly of fibriotic nature such as fibriotic lesional tissues, contiguous warts, contact dermatitis, and keloids, and to assist the healing of burns after surgery, comprising as active ingredient a substituted pyridone of the formula: n-(R1)-R2-2-(1H)pyridone or a pharmaceutically acceptable salt or ester thereof, where R1 is selected from methyl, ethyl, propyl, carboxyl and a carboxymethyl or carboxyethyl ester group, R2 is selected from phenyl, methylphenyl, ethylphenyl, propylphenyl, and a carboxyphenyl or carboxyethylphenyl ester group, and n is 3, 4 or 5, together with an excipient, characterized in that the excipient comprises, one or more plasticisers, one or more antioxidants, one or more gel-forming agents and sufficient pH adjusting agent to bring the pH of the formulation to a value from 4 to 8. The preferred active ingredient is 5-methyl-1-phenyl-2-(1H)pyridone (Pirfenidone).
Abstract: A composition of an analgesic choline bitartrate, and myo-inositol and method for using same are described herein.
The composition alleviates inflammation and pain due to such causes as sciatica, injury, trauma and arthritis without the negative side effect attributable to NSAIDs.
Abstract: Administration of inhibitors of carboxypeptidase E provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior and enhanced cognition. Certain &bgr;-Lactam antibiotics, most significantly, certain 1-oxa-1-dethia cephems with blood brain barrier transport, exhibit potent therapeutic neurologic activity.
Abstract: Pharmaceutical compositions incorporate compounds that affect cytokine production and/or secretion. Such compounds include aryl substituted olefinic amine compounds, pyridyloxylalkylamines and phenoxyalkylamines, and aryl substituted amine compounds, such as 3-aminophenyl amine compounds. Such pharmaceutical compositions can be used for treating a wide variety of conditions, diseases and disorders, and particularly those associated with dysfunction of cytokine production and/or secretion. Of particular interest are pharmaceutical compositions useful for preventing and treating conditions, diseases and disorders associated with undesirably high levels of cytokine production and/or secretion. Such pharmaceutical compositions are useful for treating the effects of inflammatory bowel disease, inflammation, arthritis, cachexia in neoplastics diseases or associated with AIDS, and autoimmune diseases.
Type:
Grant
Filed:
September 6, 2000
Date of Patent:
December 3, 2002
Assignee:
Targacept, Inc.
Inventors:
Merouane Bencherif, William Scott Caldwell, Gary Maurice Dull, Grayland Page Dobson
Abstract: The invention features methods of using pharmaceutically-active 2- or 3-aryl substituted imidazopyridines for the treatment of histamine H3 receptor-mediated disorders.
Type:
Grant
Filed:
March 29, 2001
Date of Patent:
December 3, 2002
Assignee:
Ortho-McNeil Pharmaceutical, Inc.
Inventors:
J. Guy Breitenbucher, Nicholas I. Carruthers, Xiaobing Li, Timothy W. Lovenberg
Abstract: A therapeutic formulation comprises a topically acceptable semisolid vehicle and carbamazepine, the vehicle consisting of components that are compatible with the carbamazepine, and the carbamazepine being in a concentration sufficient to permit a therapeutically effective amount of the carbamazepine to be absorbed from the formulation into the skin of a patient. The vehicle may be a cream, ointment, or gel. A method of treating a skin condition of a patient such as psoriasis comprises applying carbamazepine topically to the patient's skin until the condition improves. A method of administering carbamazepine to a patient comprises applying a formulation comprising carbamazepine topically to the patient's skin.